EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Clinical efficacy of subsensory sacral neuromodulation in adults with faecal incontinence: The SUBSoNIC crossover randomised controlled trial and cohort follow‐up study

Paul F Vollebregt, Yan Li Goh, Anil Bagul, Claire Chan, Tom Dudding, Paul Furlong, Shaheen Hamdy, Joanne Haviland iD, Richard Hooper, James Jones, Eleanor McAlees, Christine Norton und 8 weitere

Colorectal Disease · 2025

DOI: 10.1111/codi.70308 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Colorectal Disease, 2025. Verfasst von Paul F Vollebregt und 19 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuroscience, Surgery and Trauma, Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Fecal Incontinence, Electric Stimulation Therapy, Lumbosacral Plexus. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sacral neuromodulation (SNM) is considered the first‐line surgical treatment in adults with refractory faecal incontinence (FI). However, its clinical efficacy has not been rigorously tested in a trial setting.

Method

Randomised, multicentre, double‐blind crossover trial (two 16‐week periods) of active stimulation versus sham, and open‐label follow‐up to 58 weeks. Participants: adults aged 18–80 with refractory FI.

Interventions

Active : subsensory sacral nerve stimulation with an implanted pulse generator; Sham : identical implant but turned off. Primary outcome: FI episodes per week (paper bowel diary) during final 4 weeks of crossover periods (allowing 12 weeks' washout). Randomised allocation (1:1) to arm 1 (SNM/sham) or arm 2 (sham/SNM). Blinding: participants, surgeons, assessors; tamper‐proof tape‐masked stimulation settings. Sample size: 80 patients to detect a 30% reduction in episodes. Groups compared using a paired t ‐test, and treatment effects summarised by mean differences.

Results

Trial delivery was severely affected by COVID‐19. Thirty‐nine patients of 220 screened (arm 1: N = 17; arm 2: N = 22) were recruited at 10 sites (February 2018–July 2022), of whom only 16 (arm 1: N = 9; arm 2: N = 7) had complete primary outcome data. Of the 39, 19 completed follow‐up to 58 weeks. SNM conferred a non‐significant reduction in mean FI episodes per week compared to sham (−0.795 [95% CI: −1.5 to 0.0], p = 0.06). Improvements were observed in FI symptoms at 58 weeks compared to baseline (FI episodes per week: 3.2 [SD 3.3] vs. 6.2 [SD 5.9]).

Conclusions

The SUBSoNIC trial failed to find conclusive evidence of the experimental efficacy of SNM. Further demonstration of experimental efficacy remains important as SNM is a high‐cost and invasive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal IncontinenceElectric Stimulation TherapyLumbosacral PlexusHumansFemaleMiddle AgedMaleCross-Over StudiesAgedAdultTreatment OutcomeFollow-Up StudiesDouble-Blind MethodAged, 80 and overYoung AdultAdolescent

Stichwörter der Autor:innen

anal incontinencefaecal incontinenceneuromodulationsacral nerve stimulation

Autor:innen und Institutionen

  • Centre for Neuroscience, Surgery and Trauma, Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
  • Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Sandwell and West Birmingham NHS Trust, Birmingham, UK.
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Pragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Faculty of Medicine and Dentistry, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • University Hospital Southampton NHS Foundation Trust, Southampton, UK.

ORCID-Profile: Joanne Haviland

Förderung

  • National Institute for Health and Care Research
  • Medtronic

Zitieren

APA

Vollebregt, P. F., Goh, Y. L., Bagul, A., Chan, C., Dudding, T., Furlong, P., Hamdy, S., Haviland, J., Hooper, R., Jones, J., McAlees, E., Norton, C., O'Connell, P. R., Powar, M., Scott, S. M., Stevens, N., Tubby, K., Worthen, S., Wong, Y. L., & Knowles, C. H. (2025). Clinical efficacy of subsensory sacral neuromodulation in adults with faecal incontinence: The SUBSoNIC crossover randomised controlled trial and cohort follow‐up study. Colorectal Disease. https://doi.org/10.1111/codi.70308

Vancouver

Vollebregt PF, Goh YL, Bagul A, Chan C, Dudding T, Furlong P, et al. Clinical efficacy of subsensory sacral neuromodulation in adults with faecal incontinence: The SUBSoNIC crossover randomised controlled trial and cohort follow‐up study. Colorectal Disease. 2025. doi:10.1111/codi.70308

BibTeX
@article{Vollebregt2025,
  author = {Vollebregt, Paul F and Goh, Yan Li and Bagul, Anil and Chan, Claire and Dudding, Tom and Furlong, Paul and Hamdy, Shaheen and Haviland, Joanne and Hooper, Richard and Jones, James and McAlees, Eleanor and Norton, Christine and O'Connell, P Ronan and Powar, Michael and Scott, S Mark and Stevens, Natasha and Tubby, Kerry and Worthen, Sian and Wong, Yuk Lam and Knowles, Charles H},
  title = {Clinical efficacy of subsensory sacral neuromodulation in adults with faecal incontinence: The SUBSoNIC crossover randomised controlled trial and cohort follow‐up study},
  journal = {Colorectal Disease},
  year = {2025},
  doi = {10.1111/codi.70308}
}
Kostenlos starten →